Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Oncology

FDA Approves Replimune's Tudriqev for Advanced Melanoma After Two Previous Rejections

FDA granted accelerated approval to Tudriqev with nivolumab for advanced melanoma after two rejections. Who qualifies and what evidence is still owed.

Medical Daily

Large Trial Finds High-Dose Vitamin D Did Not Slow Metastatic Colorectal Cancer

A phase 3 trial in 455 patients found high-dose vitamin D3 did not improve survival in metastatic colorectal cancer, reversing an earlier signal.

Medical Daily

Cleveland Clinic Breaks Ground on $322 Million Avon Expansion Adding Beds, Operating Rooms and Cancer Services

Cleveland Clinic began a $322 million expansion of its Avon campus, adding beds, ORs, imaging and cancer capacity for Lorain County through 2029.

Medical Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

6 Common Stomach Cancer Risk Factors Found in Indian Kitchens and Daily Habits

The Salt in Your AchaarSalt is the oldest preservative in the Indian pantry, and achaar, papad, and salted dried fish are eaten across every region without a second thought. The problem is volume. A 2019 review published in the International Journal of Cancer found that high dietary salt intake is…

Times Life

Cervical Cancer Is Almost Entirely Preventable. So Why Does It Still Kill So Many Women in India

Numbers That Should Not ExistEvery eight minutes, an Indian woman dies of cervical cancer. That figure comes from ICMR data published in its National Cancer Registry Programme report, and it has not moved in the direction it should. India records roughly 1.25 lakh new cervical cancer cases annually and accounts…

Times Life

FDA Tells Cancer Trial Sponsors to Stop Copying Eligibility Rules That Lack Scientific Support

FDA finalized three guidances telling cancer trial sponsors to justify lab value, performance status, and washout period exclusions rather than copying them.

Medical Daily

8 Oral Cancer Warning Symptoms Indian Men Keep Ignoring, From Lesions to Screening Delays

A White Patch That Will Not Go AwayLeukoplakia, a thick white or greyish patch inside the mouth, is one of the most documented precancerous lesions in Indian men who use smokeless tobacco. A 2020 study published in the Indian Journal of Cancer found that leukoplakia was present in nearly 60%…

Times Life

Read news from The Economist, FT, and more,
with one subscription

Myeloma's Most Effective New Drugs Require a Hospital Stay to Start, and That Is Keeping Them Out of Reach for Rural Patients

Bispecific antibodies work in advanced myeloma, but startup requirements keep them at academic centers. New guidance aims to close the community gap.

Medical Daily

FDA Renamed and Updated Its Companion Diagnostics List, Including the First Test That Detects Cancer's Return in Blood

FDA updated its companion diagnostics list on July 23, adding tests that decide who gets targeted cancer drugs, including a blood-based MRD test.

Medical Daily

Andhra Pradesh teams up with AstraZeneca for next-gen cancer care model

Andhra Pradesh signed an MoU with AstraZeneca for an integrated precision oncology ecosystem. This initiative will integrate artificial intelligence and advanced genomics for cancer care. The collaboration aims to transform patient journeys from screening to follow-up. AstraZeneca will deploy AI-powered solutions for early lung cancer detection. An Integrated Genomic Solutions…

The Economic Times

FDA Approves Revtorpyk for a Breast Cancer Subgroup That Had Been Left Out of Targeted Treatment

FDA approved Revtorpyk (gedatolisib) for HR+/HER2- PIK3CA wild-type advanced breast cancer. VIKTORIA-1 showed 9.3 months of PFS versus 2.0.

Medical Daily

Scientists Apply Evolution Theory to Cancer Treatment, and Timed Drug Switching Could Beat Resistance

A Genetics study published July 22, 2026, uses evolutionary biology math models to show that timed drug switching before tumor recovery could beat cancer resistance. Here is what the approach means.

Medical Daily

FDA Expands Keytruda Approval to All Bladder Cancer Patients Before Surgery, Not Just Those Avoiding Chemo

The FDA expanded Keytruda plus Padcev to all muscle-invasive bladder cancer patients on July 10, 2026. Here is who now qualifies and what the KEYNOTE-B15 trial showed.

Medical Daily

FDA Approves First Drug Specifically for 60 Percent of Metastatic Breast Cancer Patients Who Had No Prior Options

The FDA approved gedatolisib (Revtorpyk) on July 14, 2026, for HR+/HER2- advanced breast cancer patients without a PIK3CA mutation. Here is who qualifies and what the trial showed.

Medical Daily

Get all your
news in one place.

100's of premium titles.
One news app.

The Economic Times

AstraZeneca 'magic' faces rare test after trial failure, share slide

AstraZeneca's nerve drug Wainua unexpectedly failed a late-stage heart disease trial. This setback has caused investor concern and impacted the company's share price. Investors now await results from two key oncology trials, SERENA-4 and AVANZAR. Success in these trials is crucial for maintaining confidence in AstraZeneca's research engine. The company…

Medical Daily

Treating Cancer Like an Evolving Ecosystem Could Beat Drug Resistance, New Mathematical Models Suggest

New mathematical models in Genetics published July 22 show that timed therapy switching before tumor regrowth could outperform maximum-dose cancer treatment by exploiting resistance evolution.

Medical Daily

Six Cancer Drug Approvals in One Quarter: What the FDA Cleared in Q2 2026 and Who It Helps

FDA approved 6 cancer drugs in Q2 2026, covering breast, prostate, kidney, bladder, and blood cancers. Here's what was approved, who qualifies, and what it means.

Medical Daily

A Breast Cancer Drug Decision Due July 17 Could Open a New Treatment Path for 37,000 Women a Year Who Have No Good Options Now

FDA decides on gedatolisib July 17, 2026, for HR+/HER2-/PIK3CA wild-type advanced breast cancer. A Phase 3 trial showed 76% risk reduction in progression. 37,000 patients per year.

Get all your
news in one place.

100's of premium titles.
One news app.

The Conversation

Can Ozempic prevent cancer? A doctor explains why the headlines are easy to misread

In the weeks around the 2026 annual meeting of the American Society of Clinical Oncology, my phone kept buzzing with alerts about GLP-1 drugs and cancer. The headlines were everywhere – from NPR and The Washington Post to Substack and heated exchanges on social media – all circling the same…

Medical Daily

GLP-1 Drugs Are Now Being Tested Alongside Chemotherapy in Cancer Patients

A University of Arizona trial is testing GLP-1 drugs with chemotherapy in metastatic pancreatic, colorectal, and liver cancer patients. Here's what the study asks.

AAP

Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions

MELBOURNE, Australia and INDIANAPOLIS, June 23, 2026 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, "Telix") today announces an educational webinar exploring the unmet needs in neurologic oncology (specifically glioma and glioblastoma) and how theranostics may help address these. David N. Cade, MD, Telix Group Chief Medical Officer...

AAP

Gene Solutions Hosts K-CONNECT Summit 2026, Uniting Oncology Experts Across Asia-Pacific

DA NANG, Vietnam, June 18, 2026 /PRNewswire/ -- Gene Solutions announced the successful conclusion of K-CONNECT Summit 2026, a regional scientific forum that brought together leading oncology experts, clinicians, researchers and healthcare stakeholders to discuss how Artificial Intelligence (AI) and multi-omics are reshaping cancer care across Asia-Pacific.Held in Da Nang,…

The Economic Times

Zydus Lifesciences shares fall 2% as firm acquires US-based Assertio Holdings for $166 million

Zydus Lifesciences' shares dipped 2% after completing the $166.4 million acquisition of US-based Assertio Holdings Inc. The deal, finalized through a subsidiary, makes Assertio a wholly-owned entity, bolstering Zydus's specialty and oncology supportive-care therapies pipeline. This strategic move aims to enhance the company's innovative drug offerings.

Medical Daily

Personalized mRNA Cancer Vaccine Shows Five-Year Data Stunning Oncologists with 69 Percent of Stage III IV Melanoma Patients Cancer-Free

ASCO 2026 (June 3, 2026) and Journal of Clinical Oncology: Intismeran autogene + Keytruda shows 49% sustained recurrence reduction at 5 years, 59% distant metastasis reduction, and 53% overall survival benefit in high-risk Stage III/IV melanoma. 69% of combination patients are cancer-free at 5 years.

AAP

Menarini Group Reports Data from the Phase 3 SENTRY Trial of Selinexor Plus Ruxolitinib in Myelofibrosis at The European Hematology Association (EHA) 2026 Congress

FLORENCE, Italy and NEW YORK, June 14, 2026 /PRNewswire/ -- The Menarini Group ("Menarini"), a leading international pharmaceutical and diagnostics company, and Stemline Therapeutics, Inc. ("Stemline"), a wholly-owned subsidiary of the Menarini Group focused on bringing transformational oncology treatments to cancer patients, announced that new data related to the pivotal…

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

University of Arizona

77 stories

the University of Arizona

73 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.